Tyra Biosciences, Inc. (TYRA)
28.65
+3.79
(+15.25%)
USD |
NASDAQ |
Sep 04, 16:00
28.70
+0.05
(+0.17%)
Pre-Market: 20:00
Tyra Biosciences Total Liabilities (Quarterly) : 29.70M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.70M |
| March 31, 2026 | 24.46M |
| December 31, 2025 | 24.87M |
| September 30, 2025 | 21.34M |
| June 30, 2025 | 19.35M |
| March 31, 2025 | 19.94M |
| December 31, 2024 | 21.95M |
| September 30, 2024 | 18.30M |
| June 30, 2024 | 16.42M |
| March 31, 2024 | 14.86M |
| December 31, 2023 | 21.60M |
| September 30, 2023 | 16.19M |
| Date | Value |
|---|---|
| June 30, 2023 | 11.44M |
| March 31, 2023 | 6.265M |
| December 31, 2022 | 8.352M |
| September 30, 2022 | 8.229M |
| June 30, 2022 | 8.265M |
| March 31, 2022 | 7.787M |
| December 31, 2021 | 5.226M |
| September 30, 2021 | 6.239M |
| June 30, 2021 | |
| March 31, 2021 | 159.33M |
| December 31, 2020 | 29.65M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| CG Oncology, Inc. | 56.54M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 383.36M |
| Shareholders Equity (Quarterly) | 353.66M |
| Debt to Equity Ratio | 0.0158 |
| Current Ratio | 14.91 |
| Net Debt Paydown Yield | 0.01% |